Aquestive Therapeutics (NASDAQ:AQST) Insider Sells $65,639.97 in Stock

Aquestive Therapeutics, Inc. (NASDAQ:AQST) insider Sherry Korczynski sold 15,741 shares of the stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $4.17, for a total transaction of $65,639.97. Following the transaction, the insider directly owned 241,117 shares of the company’s stock, valued at approximately $1,005,457.89. This trade represents a 6.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Aquestive Therapeutics Stock Up 2.5%

Shares of AQST traded up $0.11 during trading on Wednesday, reaching $4.31. 1,170,828 shares of the company traded hands, compared to its average volume of 5,614,740. The stock has a 50-day simple moving average of $4.13 and a 200-day simple moving average of $5.22. The stock has a market cap of $525.38 million, a PE ratio of -5.52 and a beta of 1.61. Aquestive Therapeutics, Inc. has a twelve month low of $2.12 and a twelve month high of $7.55.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings data on Wednesday, March 4th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13). The company had revenue of $13.02 million for the quarter, compared to analysts’ expectations of $13.28 million. On average, equities research analysts predict that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current year.

Trending Headlines about Aquestive Therapeutics

Here are the key news stories impacting Aquestive Therapeutics this week:

• Positive Sentiment: Analyst note/valuation — A Seeking Alpha write‑up reiterates a Buy on AQST and argues Anaphylm is closer to FDA approval after addressing CRL packaging/labeling issues; the author models an $8 fair value (≈87% upside), high adoption probabilities and eventual profitability by 2029 while warning additional financing may be needed by end‑2027. Aquestive Therapeutics: With Some Hiccups, Anaphylm Is Closer To FDA Approval
• Positive Sentiment: Broker upgrades/estimate revisions — HC Wainwright raised several near‑term EPS estimates (Q1–Q4 2026 and select 2027 quarters) and lifted its FY2026 view (from roughly -$0.61 to -$0.51), signaling modestly improved operating outlook assumptions. This reduces downside to short‑term guidance risk but the company remains loss‑making. AQST Stock Page
• Neutral Sentiment: Industry coverage — The Globe and Mail included Aquestive in a list of healthcare stocks analysts are bullish on, providing supportive media attention but no company‑specific catalytic news. Analysts Are Bullish on These Healthcare Stocks: Teva Pharmaceutical (TEVA), Aquestive Therapeutics (AQST)
• Neutral Sentiment: Corporate governance — Aquestive granted an inducement equity award to its Chief Medical Officer under Nasdaq rules; standard retention/compensation action (minor dilution/expense implications). Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)
• Negative Sentiment: Legal risk — Multiple law firms (Rosen, Johnson Fistel, Bernstein Liebhard, Faruqi & Faruqi, Gross Law) have announced or are soliciting plaintiffs for securities class actions covering purchases from June 16, 2025 to Jan 8, 2026; litigation could increase legal costs, management distraction and limit upside until resolved. Note deadlines for lead plaintiff motions are being publicized (e.g., May 4, 2026). AQST Investors Encouraged to Seek Lead Plaintiff Role in Aquestive Therapeutics Securities Class Action Case with Johnson Fistel
• Negative Sentiment: Market data anomaly — Short‑interest reports show a reported surge but contain inconsistent/erroneous values (zeros/NaN). If real, rising short interest would add selling pressure; current published figures appear unreliable and should be confirmed via exchange filings. (No external link provided.)

Institutional Trading of Aquestive Therapeutics

Several hedge funds have recently modified their holdings of the stock. Invesco Ltd. boosted its stake in shares of Aquestive Therapeutics by 20.2% in the 4th quarter. Invesco Ltd. now owns 64,993 shares of the company’s stock valued at $420,000 after buying an additional 10,920 shares during the period. Voloridge Investment Management LLC acquired a new stake in Aquestive Therapeutics in the fourth quarter valued at approximately $1,254,000. Numerai GP LLC acquired a new stake in Aquestive Therapeutics in the fourth quarter valued at approximately $789,000. Occudo Quantitative Strategies LP purchased a new position in Aquestive Therapeutics in the fourth quarter worth approximately $365,000. Finally, Millennium Management LLC grew its holdings in Aquestive Therapeutics by 19.1% during the 4th quarter. Millennium Management LLC now owns 1,535,369 shares of the company’s stock worth $9,918,000 after acquiring an additional 246,040 shares in the last quarter. 32.45% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

AQST has been the topic of several research analyst reports. Wall Street Zen upgraded Aquestive Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aquestive Therapeutics in a research report on Wednesday, January 21st. Finally, Lake Street Capital set a $6.00 price target on shares of Aquestive Therapeutics in a research report on Tuesday, February 3rd. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Aquestive Therapeutics has an average rating of “Buy” and a consensus price target of $8.80.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.